Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend erythroleukemia cells. VIII. Role of the immune system in the inhibition of visceral metastases.
DBA/2 mice were injected i.v. with IFN alpha/beta-resistant 3CI8 Friend erythroleukemia cells (FLC) which metastasize to the liver and spleen. IFN alpha/beta treatment of FLC-injected mice increased their survival time and these mice developed a resistance to a second challenge with FLC. The efficacy of IFN alpha/beta in increasing the survival time was compared between normal immunocompetent and immunodeficient mice. The anti-tumor action of IFN was markedly reduced or abolished in newborn DBA/2 mice, in adult athymic nu/nu and beige DBA/2 mice, and in BALB/c scid/scid mice. To determine the phenotype of the effector cells involved, FLC-injected DBA/2 mice were treated with antibodies to asialo-GMI, CD4, or CD8 antigens, or with cyclosporin A or silica. IFN alpha/beta treatment proved much less effective in these mice, indicating that a variety of effector cell types participated in the IFN-induced suppression of visceral metastases. Thus, an intact immune system appears to be essential to obtain optimal therapeutic effects of IFN alpha/beta in this experimental model.
Institut de Recherches Scientifiques sur le Cancer, C.N.R.S., Villejuif, Paris, France.
I
I
Gresser
C
C
Maury
C
C
Carnaud
E
E
De Maeyer
M T
MT
Maunoury
F
F
Belardelli
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D003524:Cyclosporins / Q000627:therapeutic use; D004351:Drug Resistance / Q000235:genetics; D005622:Friend murine leukemia virus; D007370:Interferon Type I / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use; D004915:Leukemia, Erythroblastic, Acute / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000517:prevention & control / Q000556:secondary*; D051379:Mice; D008811:Mice, Inbred DBA; D008817:Mice, Mutant Strains; D008819:Mice, Nude; D009360:Neoplastic Cells, Circulating; D013160:Splenic Neoplasms / Q000517:prevention & control / Q000556:secondary*; D014412:Tumor Virus Infections / Q000188:drug therapy* / Q000235:genetics
D000906:Antibodies; D003524:Cyclosporins; D007370:Interferon Type I; D007376:Interleukin-2